Gilead Sciences, Inc. - Feb 7, 2024 Form 3 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Role
10%+ Owner
Signature
Gilead Sciences, Inc. By: /s/ Andrew D. Dickinson
Stock symbol
KYTX
Transactions as of
Feb 7, 2024
Transactions value $
$0
Form type
3
Date filed
2/7/2024, 05:35 PM
Previous filing
Jan 31, 2024
Next filing
Feb 13, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding KYTX Series A-2 Convertible Preferred Stock Feb 7, 2024 Common Stock 1.51M Direct F1, F2
holding KYTX Series B Convertible Preferred Stock Feb 7, 2024 Common Stock 1.7M Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The convertible preferred stock is convertible at any time, at the holder's election, on a one-for-one basis, and will convert automatically upon the issuer's consummation of an initial public offering. The preferred stock has no expiration date.
F2 Reflects a 1-for-4.5511 reverse stock split of the issuer's common stock, effected on January 30, 2024.